Page last updated: 2024-08-24

ruthenium chloride (rucl3) and Benign Neoplasms

ruthenium chloride (rucl3) has been researched along with Benign Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anzellotti, A; Rieber, M; Sánchez-Delgado, RA; Strasberg Rieber, M	1

Other Studies

1 other study(ies) available for ruthenium chloride (rucl3) and Benign Neoplasms

Article	Year
Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor. International journal of cancer, 2004, Nov-10, Volume: 112, Issue:3 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Caspase 3; Caspases; Cisplatin; Clotrimazole; Combined Modality Therapy; Cytochromes c; Drug Synergism; Enzyme Activation; ErbB Receptors; Humans; Ketoconazole; Membrane Proteins; Mitochondria; Neoplasms; Poly(ADP-ribose) Polymerases; Ruthenium Compounds; Spheroids, Cellular; Superoxide Dismutase; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2004

Article

Year

Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor.

International journal of cancer, 2004, Nov-10, Volume: 112, Issue:3

Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Caspase 3; Caspases; Cisplatin; Clotrimazole; Combined Modality Therapy; Cytochromes c; Drug Synergism; Enzyme Activation; ErbB Receptors; Humans; Ketoconazole; Membrane Proteins; Mitochondria; Neoplasms; Poly(ADP-ribose) Polymerases; Ruthenium Compounds; Spheroids, Cellular; Superoxide Dismutase; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2004